Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
Janux Therapeutics Initiated With an Outperform at Leerink
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Innovative TRACTr Platform and Promising Prospects for Janux Therapeutics: An Analysis of JANX007's Potential in Prostate Cancer Treatment